Provided by Tiger Fintech (Singapore) Pte. Ltd.

Veru Inc.

0.5409
+0.01803.44%
Post-market: 0.5250-0.0159-2.94%19:39 EDT
Volume:680.91K
Turnover:366.79K
Market Cap:79.18M
PE:-2.06
High:0.5477
Open:0.5329
Low:0.5202
Close:0.5229
Loading ...

BRIEF-Veru Announces The Sale Of The FC2 Female Condom Business

Reuters
·
31 Dec 2024

Veru Inc - Expects $12.5 Million Proceeds After Deductions From Fc2 Sale

THOMSON REUTERS
·
31 Dec 2024

Veru Inc - to Reduce Headcount by Approximately 90% After Fc2 Sale

THOMSON REUTERS
·
31 Dec 2024

Veru Announces the Sale of the Fc2 Female Condom® (Internal Condom) Business

THOMSON REUTERS
·
31 Dec 2024

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

GlobeNewswire
·
31 Dec 2024

Veru Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Dec 2024

Is Veru (NASDAQ:VERU) Using Debt In A Risky Way?

Simply Wall St.
·
18 Dec 2024

MIDEAST STOCKS-Dubai hits over a decade high; Most Gulf shares muted

Reuters
·
17 Dec 2024

Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
17 Dec 2024

Veru Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
17 Dec 2024

US Penny Stocks To Consider In December 2024

Simply Wall St.
·
17 Dec 2024

The past three years for Veru (NASDAQ:VERU) investors has not been profitable

Simply Wall St.
·
11 Dec 2024

Veru Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
03 Dec 2024

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

GlobeNewswire
·
26 Nov 2024

Veru Price Target Maintained With a $5.00/Share by Oppenheimer

Dow Jones
·
06 Nov 2024

Oppenheimer would be buyers of Veru ahead of January’s top line readout

TIPRANKS
·
06 Nov 2024

Veru Inc - Topline Results of Phase 2B Extension Study Expected in Q2 2025

THOMSON REUTERS
·
05 Nov 2024

Veru Inc - Topline Results From Phase 2B Quality Trial Expected in January 2025

THOMSON REUTERS
·
05 Nov 2024

Veru Inc - Enobosarm Generally Well-Tolerated With No Increase in Gastrointestinal Side Effects

THOMSON REUTERS
·
05 Nov 2024

Veru Announces Meta-Analysis of Body Composition Data From Older Patients With Obesity Which Supports Potential for Enobosarm to Optimize Weight Loss at Obesityweek

THOMSON REUTERS
·
05 Nov 2024